


EMA's engagement with patients



Patient engagement: Integral element of EMA activities







Increasing and varied involvement in different activities

Representing their community


- •Management Board
- •EMA Scientific Committee Members

Representing their organisations

- Working Party (PCWP or HCPWP)
- EMA consultations
- Workshops

Individual experts

- Scientific Advice / Protocol Assistance Procedures
- Scientific Advisory/ad hoc expert Groups
- Scientific Committee consultations
- Review of documents



Patients to contribute directly to scientific discussions

- Committee (full voting) membership
- Scientific advice procedures
- Scientific Advisory Groups (SAGs) / Ad-hoc expert group meetings
- Committees/Working Parties consultations (f2f /questionnaires/surveys)
- Stakeholder meetings
- Public hearings / meetings
- EMA workshops & public consultations on development /update of regulatory guidance
- Review of package leaflets, medicine overviews and and safety communications (appropriate language / increase awareness)





Continuous monitoring and measuring value / impact

EXAMPLE:

3 year survey \approx 300 Scientific Advice procedures:

- 52% of the patient`s comments resulted in further discussion
- 20% of the patient's input resulted in a modification of the final advice





REVIEW OF DOCUMENTS:
50% of comments led to
changes

Summary messages

Engaging with patients;

- brings everyday aspects of living with a condition into scientific discussions
- helps bridge the gap between clinical trial data and real world data
- increases transparency, awareness and understanding
- Value demonstrated; ultimately, listening to patients leads to more meaningful outcomes for all